Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

23.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.4K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

1.6K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.6K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

369
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
369

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.

The Journal of clinical endocrinology and metabolism·2026
Same author

Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.

Pituitary·2026
Same author

Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials.

Clinical endocrinology·2026
Same author

Differential expression of POMC-processing genes in corticotroph tumors.

Endocrine oncology (Bristol, England)·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Adenoma receptors and histologic characteristics determining management outcomes.

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Jul 26, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.9K

Refractory somatotroph adenomas.

Monica R Gadelha1,2,3,4, Leandro Kasuki5,6

  • 1Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital, Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br.

Pituitary
|June 14, 2023
PubMed
Summary

Most somatotroph adenomas respond to standard treatments like surgery or medication. However, aggressive tumors may not respond to these therapies, requiring alternative management strategies.

Keywords:
AcromegalyAggressive adenomasPasireotidePegvisomantSomatostatin receptor ligands

More Related Videos

Correlative Light- and Electron Microscopy Using Quantum Dot Nanoparticles
11:16

Correlative Light- and Electron Microscopy Using Quantum Dot Nanoparticles

Published on: August 7, 2016

9.8K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.8K

Related Experiment Videos

Last Updated: Jul 26, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.9K
Correlative Light- and Electron Microscopy Using Quantum Dot Nanoparticles
11:16

Correlative Light- and Electron Microscopy Using Quantum Dot Nanoparticles

Published on: August 7, 2016

9.8K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Neurosurgery

Background:

  • Somatotroph adenomas are pituitary tumors that cause excess growth hormone production.
  • Standard treatments include surgery, medical therapy, and radiotherapy.
  • A subset of these tumors exhibit aggressive behavior and resistance to conventional treatments.

Purpose of the Study:

  • To review the characteristics of aggressive somatotroph adenomas.
  • To outline current management options for refractory somatotroph adenomas.

Main Methods:

  • Literature review of somatotroph adenomas.
  • Analysis of tumor phenotype and treatment outcomes.

Main Results:

  • Aggressive somatotroph adenomas present distinct clinical and pathological features.
  • Management of refractory cases requires a multidisciplinary approach.

Conclusions:

  • Understanding the phenotype of aggressive somatotroph adenomas is crucial for effective management.
  • Further research into novel therapeutic strategies is warranted for treatment-resistant cases.